your badges 52W Range $48–$110 90% of range Analyst Rating BUY 15 analysts Price Target $112 +7% upside P/E 50.4 ROE 11.2% Net Profit Margin 7.1%

HAE Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $104.36
Market Cap (MRQ) $4.75B
P/E (TTM) 50.4
EPS (TTM) $2.07
Revenue (TTM) $1.35B
ROE (TTM) 11.2%
Debt/Equity (MRQ) 1.4
52W Range $48–$110

HAE Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 2
Ex-date Split Type
Dec. 3, 2012 2-for-1 Forward
Jan. 11, 1993 2-for-1 Forward

About Haemonetics Corporation Common Stock Company overview from Wikipedia

05 · wikidata

Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.

Today, the company has expanded and has offices located in 16 countries. The company employs more than 1,800 people and markets its products in over 50 countries. Revenue is derived nearly equally from its three major markets -- Asia, Europe, and the Americas.

History

The company was founded in 1971. Haemonetics started out producing the containers and bags required for blood collection. The Latham Bowl was a disposable container that could automate the separation of blood by centrifugation. Through the 90's, the company added additional product lines and technologies. The company opened a manufacturing facility in Holbrook, Massachusetts in 1988.

In 1995 the company purchased the Intravenous Solutions manufacturing facility in Union, South Carolina.

Additional acquisitions grew the company and expanded its services. In the following years the company branched off to making the whole plasma collection station including the machine, supplies and software for plasma collection. These acquisitions included Edmonton-based Fifth Dimension (5D) Information Systems to gain entry into the blood and plasma software industry. Further acquisitions include Chicago-based Arryx in July 2006, Information Data Management, Inc. in January 2007, the acquisition of a division of Haemoscope in 2007, the acquisition of Infonale in July 2007, and, in 2009, Chico, California-based Altivation and Tucson, Arizona-based Sebra.

On August 21, 2007, 5D and IDM were officially merged into a new subsidiary called Haemonetics Software Solutions. The employees at both Edmonton (5D) and Rosemont (IDM) continue to work from their respective offices.

Further acquisitions included the April 2009 acquisition of Neoteric Technology Ltd and the April 2010 acquisition of California-based Global Med Technologies, Inc. Haemonetics acquired the Pall Corporation's transfusion medicine business on August 1, 2012 for ~$550 million.

In April 2024, it was announced Haemonetics had completed its acquisition of the Chicago-headquartered medical device temperature regulation manufacturer, Attune Medical for $160 million.

Product categories

Haemonetics products can be considered as belonging to two broad categories. Donor products (marketed to the blood donation industry, these include products that automate the blood donation process, automate the processing of blood, support pathogen inactivation and bacterial detection of blood, and test blood hematocrit); and products that are marketed to the surgical suite for blood loss management for patients. These products include surgical blood salvage (or "autotransfusion") devices, surgical field blood suction systems, and blood and patient warming systems.

Hemostasis

TEG 5000

Kaolin TEG

Kaolin TEG with Heparinase

RapidTEG

TEG Functional Fibrinogen

TEG PlateletMapping

TEG 6S

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

sectorHealth Care industryHealth Care employees3,009 countryUS

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$1.33B
2017-04-01 → 2026-03-28
EPS$2.05
2017-04-01 → 2026-03-28
Free Cash Flow$260M
2017-04-01 → 2026-03-28
Net margin7.1%
2017-04-01 → 2026-03-28
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend HAE 5Y avg Peer Median Verdict
P/E (TTM) 50.45Y avg ≈39.1 ≈39.1 28.6 Overvalued
P/S (TTM) 3.55Y avg ≈2.8 ≈2.8 2.6 Fair value
P/B (MRQ) 5.75Y avg ≈4.2 ≈4.2 2.1 Overvalued
EV / EBITDA 36.45Y avg ≈29.3 ≈29.3 17.9 Overvalued
Price / FCF (TTM) 16.35Y avg ≈27.4 ≈27.4 · ·
Price / Cash Flow (TTM) 14.55Y avg ≈16.6 ≈16.6 17.6 Undervalued
EV / Revenue 4.35Y avg ≈3.4 ≈3.4 · ·
EV / FCF 21.95Y avg ≈32.5 ≈32.5 · ·
Price / Tangible Book (MRQ) 11.8 · · ·
PEG Ratio ≈8.8 · · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 5.0%
Next Report Nov 04, 2026
PeriodReportEPS ActualEPS EstSurprise
March 31, 2027 Aug 5, 2026 $1.14 $1.09 4.8%
June 30, 2026 $1.14 $1.09 4.8%
March 31, 2026 $1.29 $1.28 0.42%
Dec. 31, 2025 $1.31 $1.26 3.7%
Sept. 30, 2025 $1.27 $1.12 13.3%
June 30, 2025 $1.10 $1.03 7.2%
March 31, 2025 $1.24 $1.23 0.62%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 16
Metric Trend 202620252024202320222021202020192018201720162015
Revenue $1.33B$1.36B$1.31B$1.17B$993M$870M$988M$968M$904M$886M$909M$910M
Cost of Revenue $546M$612M$618M$554M$488M$473M$504M$550M$492M$508M$503M$476M
Gross Profit $788M$749M$692M$615M$506M$398M$485M$418M$412M$378M$406M$434M
R&D Expense $60M$63M$54M$50M$47M$33M$31M$36M$39M$38M$45M$54M
SG&A Expense $442M$437M$430M$377M$340M$275M$282M$273M$317M$302M$317M$337M
Operating Expenses $631M$527M$527M$459M$425M$308M$381M$334M$356M$398M$450M$394M
Operating Income $157M$222M$165M$156M$81M$90M$103M$84M$56M$-19M$-44M$41M
Other Non-op $-29M$-10M$-13M$-15M$-17M$-17M$-16M$-10M$-5M$-8M$-9M$-9M
Pretax Income $128M$212M$152M$141M$64M$73M$87M$74M$60M$-27M$-53M$31M
Income Tax $31M$44M$34M$26M$20M$-7M$11M$19M$14M$-1M$2M$14M
Net Income $97M$168M$118M$115M$43M$79M$77M$55M$46M$-26M$-56M$17M
EPS (Basic) $2.06$3.33$2.32$2.27$0.85$1.57$1.51$1.07$0.86$-0.51$-1.09$0.33
EPS (Diluted) $2.05$3.31$2.29$2.24$0.84$1.55$1.48$1.04$0.85$-0.51$-1.09$0.32
Shares (Basic) 47,179,00050,330,00050,706,00050,783,00051,047,00050,688,00050,692,00051,533,00052,755,00051,524,00050,910,00051,533,000
Shares (Diluted) 47,354,00050,730,00051,397,00051,420,00051,353,00051,292,00051,815,00052,942,00053,501,00051,524,00050,910,00052,089,000
EBITDA $157M$222M$165M$156M$81M$90M$103M$84M$56M$-19M$-44M$41M
Balance Sheet 25
Metric Trend 202620252024202320222021202020192018201720162015
Cash & Equivalents $245M$307M$179M$284M$259M$192M$137M$169M$180M$140M$115M$161M
Receivables $217M$203M$207M$179M$159M$128M$165M$185M$151M$153M$157M$146M
Inventory $306M$365M$317M$259M$293M$323M$270M$194M$161M$177M$187M$211M
Prepaid Expense $66M$60M$66M$47M$44M$51M$31M$27M$29M$41M$29M$40M
Current Assets $835M$935M$769M$770M$756M$694M$604M$576M$521M$510M$488M$558M
PP&E (Net) $306M$284M$311M$311M$258M$218M$253M$344M$332M$324M$338M$322M
PP&E (Gross) $842M$837M$959M$944M$869M$817M$832M$933M$873M$807M$786M$732M
Accum. Depreciation $536M$553M$648M$633M$611M$600M$579M$589M$541M$484M$449M$410M
Goodwill $656M$604M$565M$466M$467M$466M$211M$211M$211M$211M$268M$334M
Intangibles $448M$456M$406M$276M$310M$365M$133M$128M$157M$178M$204M$245M
Other Non-current Assets $142M$164M$136M$107M$63M$71M$62M$12M$12M$12M$14M$11M
Total Assets $2.40B$2.45B$2.20B$1.93B$1.86B$1.82B$1.27B$1.27B$1.24B$1.24B$1.32B$1.49B
Accounts Payable $51M$67M$73M$64M$58M$50M$51M$63M$55M$43M$40M$48M
Current Liabilities $283M$578M$300M$252M$442M$253M$275M$236M$385M$211M$186M$189M
Capital Leases $41M$50M$58M$56M$56M$63M$52M·····
Deferred Tax $38M$63M$63M$36M$29M$44M$11M$20M$7M$12M$21M$33M
Other Non-current Liabilities $59M$68M$75M$75M$80M$100M$89M$29M$34M$22M$26M$32M
Long-term Debt $1.24B$1.22B$808M$766M$774M$708M$382M$350M$254M$316M$408M$430M
Total Debt $1.22B$1.22B$808M$766M$774M$708M$382M$350M$254M$315M$408M$428M
Common Stock $453.0K$482.0K$508.0K$504.0K$511.0K$509.0K$503.0K$510.0K$523.0K$523.0K$509.0K$517.0K
Retained Earnings $279M$352M$360M$253M$202M$158M$79M$161M$267M$290M$316M$420M
AOCI $-38M$-55M$-36M$-30M$-26M$-30M$-45M$-30M$-19M$-33M$-35M$-22M
Stockholders' Equity $796M$821M$960M$818M$749M$732M$587M$668M$752M$740M$722M$826M
Liabilities + Equity $2.40B$2.45B$2.20B$1.93B$1.86B$1.82B$1.27B$1.27B$1.24B$1.24B$1.32B$1.49B
Shares Outstanding 45,252,66748,215,89950,787,85950,448,51951,124,24050,868,82050,322,93051,019,91852,342,96552,255,49550,932,34851,670,969
Cash Flow 16
Metric Trend 202620252024202320222021202020192018201720162015
D&A $112M$116M$97M$93M$98M$84M$110M$109M$89M$90M$90M$86M
Stock-based Comp $34M$30M$28M$26M$24M$26M$20M$17M$13M$9M$7M$14M
Deferred Tax $-26M$-6M$-11M$6M$5M$-21M$-7M$13M$-6M$-7M$-1M$4M
Amort. of Intangibles $50M$56M$41M$42M$57M$41M$34M$25M$32M$37M$59M$34M
Restructuring $3M$14M$14M$657.0K$4M$1M$4M$395.0K$31M$22M$23M$37M
Operating Cash Flow $293M$182M$182M$273M$172M$109M$158M$159M$220M$160M$122M$127M
CapEx $33M$39M$38M$191M$97M$37M$49M$119M$75M$76M$102M$122M
Investing Cash Flow $-180M$-162M$-322M$-144M$-86M$-425M$-57M$-116M$-63M$-73M$-105M$-122M
Debt Issued ······$0$348M$0$0·$0
Net Debt Issued ·$-5M$-12M$-10M$-18M$-22M$-13M$81M$-62M$-43M$-21M$-9M
Stock Repurchased $175M$225M$0$75M$0$0$175M$160M$100M$0$61M$39M
Net Stock Activity $-175M$-225M$0$-75M$0$0$-175M$-160M$-100M$0$-61M$-39M
Financing Cash Flow $-178M$109M$38M$-100M$-16M$367M$-131M$-51M$-121M$-60M$-63M$-33M
Net Change in Cash $-61M$128M$-106M$25M$67M$55M$-32M$-11M$41M$24M$-46M$-32M
Taxes Paid $61M····$12M$12M$8M$9M$7M$8M$11M
Free Cash Flow $260M$142M$115M$163M$76M$72M$109M$40M$146M$84M$19M$5M
Profitability 8
Metric Trend 202620252024202320222021202020192018201720162015
Gross Margin 59.0%55.0%52.8%52.6%50.9%45.7%49.0%43.1%45.6%42.7%44.7%47.7%
Operating Margin 11.8%16.3%12.6%13.4%8.1%10.3%10.5%8.6%6.2%-2.2%-4.8%4.5%
Net Margin 7.3%12.3%9.0%9.9%4.4%9.1%7.7%5.7%5.0%-3.0%-6.1%1.9%
Pretax Margin 9.6%15.6%11.6%12.1%6.4%8.4%8.8%7.6%6.6%-3.1%-5.9%3.4%
EBITDA Margin 11.8%16.3%12.6%13.4%8.1%10.3%10.5%8.6%6.2%-2.2%-4.8%4.5%
ROA 4.0%7.2%5.7%6.1%2.4%5.1%6.0%4.4%3.7%-2.1%-4.0%1.1%
ROE 11.8%19.4%12.3%14.5%5.9%11.0%13.2%8.7%6.1%-3.6%-7.2%2.0%
ROIC 5.9%8.6%7.2%8.0%3.6%6.8%9.4%6.1%4.3%-1.8%-4.0%1.8%
Liquidity & Solvency 4
Metric Trend 202620252024202320222021202020192018201720162015
Current Ratio 3.01.62.63.11.72.72.22.41.42.42.63.0
Quick Ratio 1.60.91.31.80.91.31.11.50.91.41.51.6
Debt / Equity 1.51.50.80.91.01.00.70.50.30.40.60.5
LT Debt / Equity 1.51.10.80.90.70.90.50.50.10.30.50.5
Efficiency 3
Metric Trend 202620252024202320222021202020192018201720162015
Asset Turnover 0.60.60.60.60.50.60.80.80.70.70.60.6
Inventory Turnover 1.61.82.12.01.61.62.23.12.92.82.52.3
Receivables Turnover 6.46.76.86.96.95.95.65.85.95.76.05.9
Per Share 5
Metric Trend 202620252024202320222021202020192018201720162015
Book Value / Share $17.60$17.02$18.90$16.21$14.66$14.38$11.67$13.09$14.38$14.15$14.17$15.99
Revenue / Share $28.17$26.82$25.47$22.73$19.34$16.97$19.08$18.28$16.90$17.20$17.85$17.48
Cash Flow / Share $6.19$3.58$3.54$5.31$3.35$2.12$3.05$3.01$4.12$3.10$2.39$2.44
Cash / Share $5.42$6.36$3.52$5.64$5.08$3.78$2.73$3.32$3.44$2.67$2.26$3.11
EPS (TTM) $2.05$3.31$2.29$2.24$0.84$1.55$1.48$1.04$0.85$-0.51$-1.09$0.32
Growth Rates 9
Metric Trend 202620252024202320222021202020192018201720162015
Revenue YoY -2.0%4.0%12.0%17.7%14.1%·······
Revenue CAGR 3Y 4.5%11.1%14.6%·········
Revenue CAGR 5Y 8.9%···········
EPS YoY -38.1%44.5%2.2%166.7%-45.8%·······
EPS CAGR 3Y -2.9%58.0%13.9%·········
EPS CAGR 5Y 5.8%···········
Net Income YoY -42.0%42.6%1.9%166.1%-45.4%·······
Net Income CAGR 3Y -5.5%56.9%13.9%·········
Net Income CAGR 5Y 4.1%···········
Valuation (TTM) 14
Metric Trend 202620252024202320222021202020192018201720162015
Revenue TTM $1.33B$1.36B$1.31B$1.17B$993M$870M$988M$968M$904M$886M$909M$910M
Net Income TTM $97M$168M$118M$115M$43M$79M$77M$55M$46M$-26M$-56M$17M
Market Cap $2.45B$3.05B$4.33B$4.17B$3.26B$5.70B$5.08B$4.46B$3.83B$2.12B$1.80B$2.28B
Enterprise Value $3.42B$3.96B$4.96B$4.66B$3.78B$6.21B$5.33B$4.64B$3.90B$2.30B$2.09B$2.55B
P/E 26.419.137.336.976.072.368.284.186.1-79.5-32.4138.2
P/S 1.82.23.33.63.36.55.14.64.22.42.02.5
P/B 3.13.74.55.14.47.88.76.75.12.92.52.8
P / Tangible Book ···54.9········
P / Cash Flow 8.316.823.815.318.952.432.128.017.413.314.718.0
P / FCF 9.421.437.525.643.179.446.4110.726.325.492.4460.7
EV / EBITDA 21.817.930.129.846.869.251.555.669.5-118.4-47.662.9
EV / FCF 13.127.843.028.649.986.648.7115.226.827.5107.4514.6
EV / Revenue 2.62.93.84.03.87.15.44.84.32.62.32.8
Earnings Yield 3.8%5.2%2.7%2.7%1.3%1.4%1.5%1.2%1.2%-1.3%-3.1%0.72%

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2026-03-282025-03-292024-03-302023-04-012022-04-02
Revenue $1.33B $1.36B $1.31B $1.17B $993M
Gross Margin % 59.0% 55.0% 52.8% 52.6% 50.9%
Operating Margin % 11.8% 16.3% 12.6% 13.4% 8.1%
Net Income $97M $168M $118M $115M $43M
Diluted EPS $2.05 $3.31 $2.29 $2.24 $0.84

Institutional owners (13F) 361 filers · $4.0B total · As of Sept. 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 361
Value held $4.0B
New positions 57
Exited positions 43
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
57 (-3 vs prior Q) 43 (-12 vs prior Q) 108 (-8 vs prior Q) 122 (+10 vs prior Q) +2.2M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
BlackRock, Inc. $443,194,350 5,909,258 11.13% Shares
VANGUARD GROUP INC $381,604,971 4,761,135 9.58% Shares
NEUBERGER BERMAN GROUP LLC $313,473,399 4,179,443 7.87% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $190,979,550 2,546,394 4.79% Shares
AQR CAPITAL MANAGEMENT LLC $165,023,065 2,266,489 4.14% Shares
ARIEL INVESTMENTS, LLC $154,572,450 2,060,966 3.88% Shares
VANGUARD CAPITAL MANAGEMENT LLC $154,468,350 2,059,578 3.88% Shares
STATE STREET CORP $136,363,950 1,818,186 3.42% Shares
DIMENSIONAL FUND ADVISORS LP $118,892,744 1,585,222 2.98% Shares
CITADEL ADVISORS LLC $113,259,000 1,510,120 2.84% Shares
GEODE CAPITAL MANAGEMENT, LLC $96,559,855 1,287,240 2.42% Shares
River Road Asset Management, LLC $96,420,150 1,285,602 2.42% Shares
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $86,651,325 1,155,351 2.18% Shares
GOLDMAN SACHS GROUP INC $78,451,463 1,046,019 1.97% Shares
UBS Group AG $73,753,350 983,378 1.85% Shares
FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ $62,319,375 830,925 1.56% Shares
ROYAL BANK OF CANADA $58,518,000 780,248 1.47% Shares
Allspring Global Investments Holdings, LLC $57,269,232 765,120 1.44% Shares
DEUTSCHE BANK AG\ $47,374,725 631,663 1.19% Shares
NORTHERN TRUST CORP $47,365,650 631,542 1.19% Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $44,356,725 591,423 1.11% Shares
Boston Trust Walden Corp $43,886,100 585,148 1.10% Shares
MILLENNIUM MANAGEMENT LLC $42,780,975 570,413 1.07% Shares
Holocene Advisors, LP $41,264,625 550,195 1.04% Shares
SILVERCREST ASSET MANAGEMENT GROUP LLC $37,034,909 493,796 0.93% Shares
MORGAN STANLEY $34,961,254 466,149 0.88% Shares
BANK OF AMERICA CORP /DE/ $33,326,325 444,351 0.84% Shares
Boston Partners $30,395,842 405,892 0.76% Shares
FRANKLIN RESOURCES INC $26,060,960 347,479 0.65% Shares
North Peak Capital Management, LLC $25,730,775 343,077 0.65% Shares
LONDON CO OF VIRGINIA $25,543,299 340,574 0.64% Shares
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC $24,905,625 332,075 0.63% Shares
VANGUARD FIDUCIARY TRUST CO $24,779,850 330,398 0.62% Shares
CITIGROUP INC $24,002,775 320,037 0.60% Shares
Aristotle Capital Boston, LLC $21,721,809 289,624 0.55% Shares
FMR LLC $21,604,051 288,054 0.54% Shares
Bank of New York Mellon Corp $21,566,396 287,552 0.54% Shares
MIZUHO MARKETS AMERICAS LLC $21,166,050 282,214 0.53% Shares
JPMORGAN CHASE & CO $17,275,045 227,888 0.43% Shares
PRINCIPAL FINANCIAL GROUP INC $16,493,025 219,907 0.41% Shares
Invenomic Capital Management LP $16,216,275 216,217 0.41% Shares
GLENMEDE TRUST CO NA $15,348,975 204,653 0.39% Shares
HEARTLAND ADVISORS INC $15,000,000 200,000 0.38% Shares
Invesco Ltd. $12,976,425 173,019 0.33% Shares
SEI INVESTMENTS CO $12,546,500 167,274 0.31% Shares
Longaeva Partners L.P. $12,286,650 163,822 0.31% Shares
RHUMBLINE ADVISERS $10,812,225 144,163 0.27% Shares
AMERICAN CENTURY COMPANIES INC $10,613,250 141,510 0.27% Shares
JANUS HENDERSON GROUP PLC $10,491,810 186,163 0.26% Shares
Nuveen, LLC $10,435,425 139,139 0.26% Shares

Show all 361 institutional owners →

Activists & 5%+ owners 8 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person Feb. 6, 2004 · Initial filing · SEC
Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person Aug. 20, 2003 · Initial filing · SEC
Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person Aug. 8, 2003 · Initial filing · SEC
Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person June 24, 2003 · Initial filing · SEC
Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person June 19, 2003 · Initial filing · SEC
Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person June 3, 2003 · Initial filing · SEC
Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person May 27, 2003 · Initial filing · SEC
Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person, Undisclosed reporting person June 15, 2001 · Initial filing · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 72 insiders · 48 officers · 25 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Christopher Simon, President & CEO May 15, 2026 A 444,704 0 0 $0
Brian Concannon President & CEO Sept. 15, 2015 M 147,040 0 0 $0
James Darecca EVP, Chief Financial Officer May 15, 2026 A 54,444 0 0 $0
William P. Mr. Burke EVP, Chief Financial Officer Aug. 23, 2021 M 30,291 0 0 $0
Christopher J Lindop CFO & EVP Business Development Jan. 13, 2016 A 56,743 0 0 $0
Ronald J Ryan VP and CFO Nov. 1, 2006 P 2,101 0 0 $0
Stewart W Strong President, Global Hospital July 26, 2024 S 18,196 0 0 $0
Byron Selman President, Global Markets Oct. 25, 2016 A 23,318 0 0 $0
Peter M Allen President, Global Plasma July 6, 2015 M 34,102 0 0 $0
Kelly Michael P President, Global Markets Nov. 11, 2013 M 10,987 0 0 $0
Mikael Gordon President, Global Markets May 3, 2012 M 4,442 0 0 $0
Remi Corlin President, Asia Aug. 8, 2008 M 884 0 0 $0
Keiko Hattori President, Haemonetics Japan May 1, 2008 P 716 0 0 $0
Thomas Lawlor President, Patient Division Nov. 28, 2007 M 0 0 0 $0
Ryoji Sakai President, Japan June 14, 2007 M 0 0 0 $0
Ulrich Eckert President, Europe & Latin Am Nov. 1, 2006 P 890 0 0 $0
Yutaka Sakurada President, Japan & Asia May 2, 2005 P 2,347 0 0 $0
Frank Chan EVP, Chief Operating Officer May 15, 2026 A 32,936 0 0 $0
Kent J Davies Chief Operating Officer Oct. 23, 2015 S 16,891 0 0 $0
Farris Maryanne Maunsell VP, Chief Accounting Officer June 5, 2026 F 6,242 0 0 $0
Laurie A. Miller SVP, Human Resources June 5, 2026 F 40,987 0 0 $0
Roy Galvin EVP, Chief Commercial Officer May 15, 2026 A 39,882 0 0 $0
Michelle L Basil EVP and General Counsel May 15, 2026 A 68,829 0 0 $0
Anila Lingamneni EVP, Chief Technology Officer July 12, 2024 S 21,331 0 0 $0
Josep Llorens EVP, Global Manufacturing May 28, 2024 F 30,940 0 0 $0
Dan Goldstein VP, Corporate Controller June 13, 2022 S 4,447 0 0 $0
Jacqueline Scanlan SVP, Global Human Resources June 7, 2021 S 4,216 0 0 $0
Said Bolorforosh EVP, Chief Technology Officer Nov. 11, 2019 S 1,977 0 0 $0
Neil 122-62-507 Ryding EVP, Global Manufacturing June 7, 2018 S 15,226 0 0 $0
David Fusco EVP, Global Human Resources Oct. 25, 2016 A 16,867 0 0 $0
Sandra Jesse EVP and Chief Legal Officer Oct. 25, 2016 A 48,166 0 0 $0
Jonathan White Chief Science and Technology Oct. 26, 2015 S 30,507 0 0 $0
Susan M Hanlon VP Finance Oct. 26, 2015 S 20,464 0 0 $0
Brian R Burns EVP, Global QA/RA Oct. 23, 2015 S 16,235 0 0 $0
Dave Helsel EVP, Global Manufacturing April 13, 2015 D 13,216 0 0 $0
Kathleen Mcdaniel EVP Global Human Resources Aug. 28, 2014 S 5,013 0 0 $0
Warren Nighan JR EVP, Global QA/RA July 24, 2013 A 7,618 0 0 $0
Joseph J Forish VP, Human Resources April 30, 2013 P 17,279 0 0 $0
Phillip John Brancazio VP, Global Manufacturing May 4, 2011 P 3,052 0 0 $0
Alicia R Lopez VP, Corporate Affairs April 5, 2011 D 2,815 0 0 $0
Michael I Ruxin VP Global Software Strategies Nov. 4, 2010 P 215 0 0 $0
Brad Nutter Chairman of the Board July 29, 2010 A 10,580 0 0 $0
Robert B Ebbeling Vice President, Operations May 1, 2009 P 15,849 0 0 $0
Jan Conneely VP & GM, Arryx, Inc. May 1, 2008 P 1,041 0 0 $0
William Granville VP, Manufacturing May 1, 2008 P 12,188 0 0 $0
Mark A Popovsky VP, Corporate Medical Director May 1, 2008 P 4,891 0 0 $0
Stephen Swenson VP & General Mgr, Global Plasm May 1, 2008 P 3,024 0 0 $0
William Roche Still VP & Gen Mrg, Therapeutics Bus May 4, 2007 M 4,193 0 0 $0
Lloyd Emerson Johnson Director July 24, 2026 A 15,471 0 0 $0
Diane M Bryant Director July 24, 2026 A 9,664 0 0 $0
Claire Pomeroy Director July 24, 2026 A 19,410 0 0 $0
Ellen M Zane Director July 24, 2026 A 21,911 0 0 $0
Martin D Madaus Director July 24, 2026 A 2,538 0 0 $0
Mark W Kroll Director July 24, 2026 A 27,295 1 0 $98,784
Michael J Coyle Director July 24, 2026 A 17,932 0 0 $0
Robert E Abernathy Director July 24, 2026 A 27,519 0 0 $0
Charles J Dockendorff Director July 24, 2025 A 7,126 0 0 $0
Catherine M Burzik Director Aug. 5, 2022 A 19,545 0 0 $0
Richard J Meelia Director Feb. 4, 2021 M 32,050 0 0 $0
Ronald G Gelbman Director Nov. 11, 2019 M 48,384 0 0 $0
Pedro P Granadillo Director Nov. 8, 2018 S 15,335 0 0 $0
Susan Bartlett Foote Director Nov. 10, 2017 M 20,740 0 0 $0
Ronald Merriman Director May 22, 2017 M 17,807 0 0 $0
Lawrence C Best Director June 12, 2014 M 10,001 0 0 $0
Paul Black Director July 24, 2013 A 8,981 0 0 $0
Ronald A Matricaria Director May 5, 2006 A · 0 0 $0
Benjamin L Holmes Director Jan. 31, 2005 M · 0 0 $0
Donna C E Williamson Director June 23, 2004 M 1,300 0 0 $0
Harvey G Klein Director May 5, 2004 A · 0 0 $0
Anthony Pare · June 30, 2008 M 2,523 0 0 $0
James O'Shaughnessy · May 1, 2008 P 3,781 0 0 $0
Mark Beucler · May 1, 2008 P 1,989 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 65 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
JSML · Janus Detroit Street Trust 1.11% 46,966 NS July 31, 2026 N-PORT
JSMD · Janus Detroit Street Trust 0.91% 112,014 NS July 31, 2026 N-PORT
ROSC · Lattice Strategies Trust 0.85% 6,121 NS July 31, 2026 N-PORT
DWAS · Invesco Exchange-Traded Fund Trust … 0.37% 14,249 SH Oct. 2, 2026 Daily
FYC · First Trust Exchange-Traded AlphaDE… 0.31% 46,806 NS July 31, 2026 N-PORT
IWO · iShares Trust 0.30% 419,058 SH Sept. 11, 2026 Daily
PRFZ · Invesco Exchange-Traded Fund Trust 0.27% 68,060 SH Oct. 2, 2026 Daily
VTWG · VANGUARD SCOTTSDALE FUNDS 0.20% 47,624 SH Aug. 19, 2026 Daily
BKSE · BNY Mellon ETF Trust 0.17% 1,770 NS July 31, 2026 N-PORT
JPSE · J.P. Morgan Exchange-Traded Fund Tr… 0.16% 11,309 NS July 31, 2026 N-PORT
QVMM · Invesco Exchange-Traded Fund Trust … 0.16% 6,183 SH Oct. 2, 2026 Daily
IWM · iShares Trust 0.16% 1,206,787 SH Sept. 11, 2026 Daily
SMDX · Tidal Trust III 0.15% 2,335 NS July 31, 2026 N-PORT
NUSC · Nushares ETF Trust 0.15% 23,101 NS July 31, 2026 N-PORT
PKW · Invesco Exchange-Traded Fund Trust 0.15% 24,033 SH Oct. 2, 2026 Daily
BBSC · J.P. Morgan Exchange-Traded Fund Tr… 0.15% 12,150 NS July 31, 2026 N-PORT
FSMD · FIDELITY COVINGTON TRUST 0.15% 43,448 NS July 31, 2026 N-PORT
RSSL · Global X Funds 0.13% 22,588 NS July 31, 2026 N-PORT
IVOG · VANGUARD ADMIRAL FUNDS 0.11% 27,512 SH Aug. 19, 2026 Daily
VTWO · VANGUARD SCOTTSDALE FUNDS 0.11% 271,486 SH Aug. 19, 2026 Daily
EBIT · Harbor ETF Trust 0.11% 154 NS July 31, 2026 N-PORT
PTMC · Pacer Funds Trust 0.11% 5,030 NS July 31, 2026 N-PORT
ESML · iShares Trust 0.11% 29,599 SH Sept. 11, 2026 Daily
DFAT · Dimensional ETF Trust 0.10% 173,703 NS July 31, 2026 N-PORT
IVOO · VANGUARD ADMIRAL FUNDS 0.10% 74,976 SH Aug. 19, 2026 Daily
MIDU · Direxion Shares ETF Trust 0.09% 682 NS July 31, 2026 N-PORT
DFAS · Dimensional ETF Trust 0.08% 150,472 NS July 31, 2026 N-PORT
IVOV · VANGUARD ADMIRAL FUNDS 0.08% 15,968 SH Aug. 19, 2026 Daily
FYX · First Trust Exchange-Traded AlphaDE… 0.07% 11,631 NS July 31, 2026 N-PORT
FAD · First Trust Exchange-Traded AlphaDE… 0.06% 4,239 NS July 31, 2026 N-PORT
FHLC · FIDELITY COVINGTON TRUST 0.06% 22,085 NS July 31, 2026 N-PORT
ISCG · iShares Trust 0.06% 5,407 SH Sept. 11, 2026 Daily
RWK · Invesco Exchange-Traded Fund Trust … 0.06% 6,859 SH Oct. 2, 2026 Daily
VBK · VANGUARD INDEX FUNDS 0.05% 302,003 SH Aug. 19, 2026 Daily
VHT · VANGUARD WORLD FUND 0.05% 139,826 SH Aug. 19, 2026 Daily
WSML · iShares Trust 0.05% 3,039 SH Sept. 11, 2026 Daily
VXF · VANGUARD INDEX FUNDS 0.04% 533,077 SH Aug. 19, 2026 Daily
VB · VANGUARD INDEX FUNDS 0.04% 1,042,525 SH Aug. 19, 2026 Daily
VBR · VANGUARD INDEX FUNDS 0.04% 331,074 SH Aug. 19, 2026 Daily
DXUV · Dimensional ETF Trust 0.03% 2,112 NS July 31, 2026 N-PORT
DFUV · Dimensional ETF Trust 0.02% 40,194 NS July 31, 2026 N-PORT
DFAC · Dimensional ETF Trust 0.02% 104,425 NS July 31, 2026 N-PORT
DFSU · Dimensional ETF Trust 0.02% 4,745 NS July 31, 2026 N-PORT
DCOR · Dimensional ETF Trust 0.02% 6,430 NS July 31, 2026 N-PORT
OMFS · Invesco Exchange-Traded Self-Indexe… 0.02% 392 SH Oct. 2, 2026 Daily
DFAU · Dimensional ETF Trust 0.01% 14,641 NS July 31, 2026 N-PORT
VTWV · VANGUARD SCOTTSDALE FUNDS 0.01% 2,320 SH Aug. 19, 2026 Daily
ESGV · VANGUARD WORLD FUND 0.01% 10,376 SH Aug. 19, 2026 Daily
IUSG · iShares Trust 0.01% 23,921 SH Sept. 11, 2026 Daily
IWV · iShares Trust 0.01% 14,081 SH Sept. 11, 2026 Daily
ITOT · iShares Trust 0.01% 61,263 SH Sept. 11, 2026 Daily
DFUS · Dimensional ETF Trust 0.01% 15,447 NS July 31, 2026 N-PORT
IUSV · iShares Trust 0.01% 16,215 SH Sept. 11, 2026 Daily
TILT · FlexShares Trust 0.00% 948 NS July 31, 2026 N-PORT
VTI · VANGUARD INDEX FUNDS 0.00% 1,441,997 SH Aug. 19, 2026 Daily
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0.00% 37,682 SH Aug. 19, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS 0.00% 3,899 SH Aug. 19, 2026 Daily
IJH · iShares Trust · 1,630,595 SH Sept. 11, 2026 Daily
IJK · iShares Trust · 161,240 SH Sept. 11, 2026 Daily
IJJ · iShares Trust · 94,617 SH Aug. 21, 2026 Daily
IWN · iShares Trust · 24,317 SH Sept. 11, 2026 Daily
XJH · iShares Trust · 6,379 SH Sept. 8, 2026 Daily
ISCB · iShares Trust · 2,011 SH Sept. 11, 2026 Daily
ISCV · iShares Trust · 6,131 SH Sept. 11, 2026 Daily
SMLF · iShares Trust · 28,971 SH Sept. 11, 2026 Daily

HAE Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 15 analysts BUY
Median target $116.50 +11.6%
5 33.3% Strong Buy
6 40.0% Buy
4 26.7% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

10 analysts · 2026-10-01

Mean target $111.50 +6.8%

Now Current price $104.36
Low$86.00 Mean$111.50 High$125.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
HAE $2.45B 26.4 -2.0% 7.3% 11.8% 59.0%
COO $13.70B 37.4 5.1% 9.2% 4.6% 65.5%
ALGN $11.14B 27.6 0.90% 10.2% 10.3% 67.2%
LNTH $4.30B 19.5 0.50% 15.2% 20.7% 61.1%
MMED $3.71B -10.2 14.2% -10.7% -9.3% 54.2%
MMSI $5.24B 41.4 11.8% 8.5% 8.4% 48.7%
QDEL $1.99B -1.8 -1.9% -41.4% -48.0% ·
ICUI $3.52B 4755.7 -6.3% 0.03% 0.03% 36.8%
XRAY $2.28B -3.8 -3.0% -16.2% -36.4% 50.0%
NEOG $1.95B -224.2 -2.7% -0.91% -0.38% 46.9%
UFPT $1.71B 25.4 19.5% 11.3% 16.9% 28.3%

Latest News Recent headlines mentioning this company

23
Haemonetics Q4 Earnings Call Highlights Yahoo Finance · 4 months, 3 weeks ago Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation Yahoo Finance · 5 months, 2 weeks ago

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 6, 2026